Literature DB >> 12969532

[Analysis of lymph node metastases of 217 cases of thoracic esophageal carcinoma and its impact on prognosis].

Feng-Shan An1, Jin-Qiu Huang, Shao-Hu Chen.   

Abstract

BACKGROUND &
OBJECTIVE: At present, the range of lymph node dissection in treatment of thoracic esophageal cancer is still controversial. This study was designed to explore the status of lymph node metastases of thoracic esophageal carcinoma and its influence on the prognosis and to seek reasonable dissecting range of lymph nodes.
METHODS: A retrospective study was performed on the clinical data of 217 patients who had underwent radical operation through three-field lymphadenectomy. Nine distinguishing clinicopathological factors possibly influencing survival rate were chosen. A multivariate analysis of these factors was performed by the computerized Cox proportional hazards model.
RESULTS: The 1-, 3-, and 5-year survival rates of all patients were 82.6%, 59.8%, and 48.8%, respectively. The lymph node metastasis rate was 62.6% and the leaping metastasis rate of lymph nodes was 5.5%. In 3989 lymph nodes dissected, metastases were detected in 454 (11.38%). The lymph node metastasis rates present in neck, thoracic mediastinum, and abdominal cavity were 31.7%, 21.2%, and 12.1% in upper-thoracic esophageal carcinoma, 21.9%, 30.5%, and 15.6% in middle-thoracic carcinoma, 9.75%, 12.7%, and 34.5% in lower-thoracic carcinoma, respectively. Degree of tumor differentiation, depth of tumor invasion, and lymphatic vessels invasion were the factors influencing lymph nodes metastases, but the length of tumor was not. According to multivariate analysis, depth of tumor invasion, tumor differentiation, the number of lymph nodes metastatic field, and tumor location were of prognostic significance. With the increasing of the number of lymph nodes metastatic field, the survival rate of the patients dropped gradually(P = 0.0284).
CONCLUSION: Lymph node metastasis especially the number of lymph node metastatic field is one of key factors affecting the prognosis of patients. Because of the upward, downward, and leaping spreading of esophageal carcinoma cells to the lymph nodes, the patients with thoracic esophageal carcinoma should be given radical operation through three-field lymphadenectomy to promote the 5-years survival rate.

Entities:  

Mesh:

Year:  2003        PMID: 12969532

Source DB:  PubMed          Journal:  Ai Zheng


  6 in total

1.  A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy.

Authors:  X Ding; J Zhang; B Li; Z Wang; W Huang; T Zhou; Y Wei; H Li
Journal:  Br J Radiol       Date:  2012-06-14       Impact factor: 3.039

2.  Video-assisted radical thoracoscopic and laparoscopic surgery for esophageal carcinoma.

Authors:  Changhong Lian; Qiang Zhao; Shuzhe Xie; Yingming Song; Huiqing Zhang; Zhengyi Jin
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

3.  The N-classification for esophageal cancer staging: should it be based on number, distance, or extent of the lymph node metastasis?

Authors:  Qi-Rong Xu; Xue-Peng Zhuge; He-Lin Zhang; Yu-Min Ping; Long-Qi Chen
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

4.  Prognostic significance and role of thoracic lymph node metastasis based on Chinese expert consensus in esophageal cancer.

Authors:  Qi-Xin Shang; Yu-Shang Yang; Wei-Peng Hu; Yong Yuan; Ai-Fang Ji; Long-Qi Chen
Journal:  Ann Transl Med       Date:  2019-08

5.  The prognostic value of nodal skip metastasis in resectable thoracic esophageal squamous cell carcinoma.

Authors:  Ge Song; Wang Jing; Song Xue; Hongbo Guo; Jinming Yu
Journal:  Onco Targets Ther       Date:  2017-05-25       Impact factor: 4.147

6.  Proposed revision of N categories to the 8th edition of the AJCC-TNM staging system for non-surgical esophageal squamous cell cancer.

Authors:  Kai Hu; Ning Kang; Yang Liu; Dong Guo; Wang Jing; Jiamei Lu; Tianmeng Tan; Caitiao Lv; Yuyan Deng; Jianxiong Long; Rensheng Wang; Jinming Yu
Journal:  Cancer Sci       Date:  2018-12-22       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.